The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Interim open-label phase 1 results of misetionamide (GP-2250): A small molecule antineoplastic targeting three major transcription factors.

Anup  Kasi

Consulting or Advisory Role - Cardinal Health; Ipsen

Research Funding - Ability Pharma (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Boundless Bio (Inst); Cardiff Oncology (Inst); Cend Therapeutics (Inst); FibroGen (Inst); Geistlich Pharma (Inst); Novita Pharmaceuticals (Inst); Novocure (Inst); Rafael Pharmaceuticals (Inst); TESARO (Inst)

Jose  Iglesias

Consulting or Advisory Role - ALLARITY THERAPEUTICS; Amplia Therapeutics; Carina Biotech; DUO ONCOLOGY; Epsilogen; HIberCell; Panavance Therapeutics